TOBI

At a Glance
Therapeutic Area:
Anti-Infectives (cystic fibrosis)
Approved Applications:
For the management of cystic fibrosis patients with chronic pulmonary P. aeruginosa infections (the most common type of bacterial lung infection in people with CF).
Applications In Development:
N/A
Acquisition Date:
January 1999
Royalty Seller:
N/A
 

Marketer:
 

Latest News

  • No results
© 2014 Royalty Pharma, RP Management LLC. All Rights Reserved.